50 related articles for article (PubMed ID: 11866870)
1. A new model for random screening inhibitors of vascular endothelial growth factor receptor 1 kinase.
Zhuang SF; Zhou CH; Qian J; Qian Z; Shibuya M; Ye QZ
Acta Pharmacol Sin; 2002 Feb; 23(2):117-23. PubMed ID: 11866870
[TBL] [Abstract][Full Text] [Related]
2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
3. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
4. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
6. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
7. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
[TBL] [Abstract][Full Text] [Related]
8. [Cloning, expression and characterization of human vascular endothelial growth factor receptor 1 tyrosine kinase].
Zhuang SF; Ye QZ
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2002 Jan; 34(1):39-44. PubMed ID: 11958132
[TBL] [Abstract][Full Text] [Related]
9. Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase.
Zhao G; Peery RB; Yingling JM
Anal Biochem; 2007 Jan; 360(2):196-206. PubMed ID: 17141171
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
List AF; Glinsmann-Gibson B; Stadheim C; Meuillet EJ; Bellamy W; Powis G
Exp Hematol; 2004 Jun; 32(6):526-35. PubMed ID: 15183893
[TBL] [Abstract][Full Text] [Related]
11. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
Guo Y; Wang S; Hoot DR; Clinton SK
J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel angiogenesis inhibitors.
Sridhar J; Akula N; Sivanesan D; Narasimhan M; Rathinavelu A; Pattabiraman N
Bioorg Med Chem Lett; 2005 Sep; 15(18):4125-9. PubMed ID: 15993586
[TBL] [Abstract][Full Text] [Related]
13. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.
Lacal PM; Ruffini F; Pagani E; D'Atri S
Int J Oncol; 2005 Dec; 27(6):1625-32. PubMed ID: 16273219
[TBL] [Abstract][Full Text] [Related]
14. Expression and purification of catalytic domain of human macrophage elastase for high throughput inhibitor screening.
Cheng DH; Shen Q; Qian J; Qian Z; Ye QZ
Acta Pharmacol Sin; 2002 Feb; 23(2):143-51. PubMed ID: 11866875
[TBL] [Abstract][Full Text] [Related]
15. Expression and purification of human vascular-endothelial-growth-factor-receptor-2 tyrosine kinase in Streptomyces for inhibitor screening.
Liu C; Guo L; Yao C; Zhang R; Li Y
Biotechnol Appl Biochem; 2008 Jun; 50(Pt 2):113-9. PubMed ID: 17824843
[TBL] [Abstract][Full Text] [Related]
16. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma.
Das B; Yeger H; Tsuchida R; Torkin R; Gee MF; Thorner PS; Shibuya M; Malkin D; Baruchel S
Cancer Res; 2005 Aug; 65(16):7267-75. PubMed ID: 16103078
[TBL] [Abstract][Full Text] [Related]
17. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
[TBL] [Abstract][Full Text] [Related]
19. Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.
Li R; Xiong DS; Shao XF; Liu J; Xu YF; Xu YS; Liu HZ; Zhu ZP; Yang CZ
Acta Pharmacol Sin; 2004 Oct; 25(10):1292-8. PubMed ID: 15456530
[TBL] [Abstract][Full Text] [Related]
20. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]